SCHEMBL23459904

SCHEMBL23459904

CC12CC3(C)CC(C)(C1)CC([C@H](NC(=O)c1ccc4ccccc4c1OCc1ccc(C(F)(F)F)cc1)C(=O)O)(C2)C3

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 5/20 0.58
▸ PPARG P37231 1/20 0.37
▸ PPARD Q03181 1/20 0.37
▸ DRD4 P21917 1/20 0.37
▸ SENP5 Q96HI0 1/20 0.37
▸ SENP2 Q9HC62 1/20 0.37
▸ SENP1 Q9P0U3 1/20 0.37
▸ KIFC1 Q9BW19 1/20 0.37
▸ MME P08473 1/20 0.36
▸ ACE P12821 1/20 0.36
▸ CPA1 P15085 1/20 0.36
▸ ACE2 Q9BYF1 1/20 0.36
▸ SLC6A5 Q9Y345 2/20 0.36
▸ TRPV1 Q8NER1 1/20 0.35
▸ TACR1 P25103 1/20 0.35
▸ MCHR1 Q99705 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25601618 1.00 CXCR2 (0.58) CXCR2PPARGPPARDDRD4SENP5
SCHEMBL23459868 0.93 CXCR2 (0.50) CXCR2PPARGPPARDSENP5SENP2
SCHEMBL25598893 0.93 CXCR2 (0.50) CXCR2PPARGPPARDSENP5SENP2
SCHEMBL23460922 0.91 CXCR2 (0.56) CXCR2PPARGPPARDDRD4SENP5
SCHEMBL23460921 0.91 CXCR2 (0.56) CXCR2PPARGPPARDDRD4SENP5
SCHEMBL38147003 0.91 CXCR2 (0.56) CXCR2PPARGPPARDDRD4SENP5
SCHEMBL23460204 0.90 CXCR2 (0.46) CXCR2PPARGPPARDTRPV1MAOA
SCHEMBL23461082 0.89 CXCR2 (0.60) CXCR2PPARGPPARDDRD4SENP5
SCHEMBL23460144 0.88 CXCR2 (0.44) CXCR2PPARGPPARDMMEACE
SCHEMBL23460143 0.88 CXCR2 (0.44) CXCR2PPARGPPARDMMEACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637414-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-26 — — US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113808-A1 CFTR-MODULATING ARYLAMIDES GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637414-B2 Arylamides and methods of use thereof CFTR, CLIC1, ABCC1 CXCR2 78/4885PPARG 1717/4885PPARD 1250/4885
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885PPARG 731/4885PPARD 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback